CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks) - Phase 2 | OGN Pipeline | CatalystAlert